Reference : Loss of Myosin Vb in colorectal cancer is a strong prognostic factor for disease recu...
Scientific journals : Article
Human health sciences : Oncology
Systems Biomedicine
http://hdl.handle.net/10993/34024
Loss of Myosin Vb in colorectal cancer is a strong prognostic factor for disease recurrence
English
Letellier, Elisabeth mailto [University of Luxembourg > Faculty of Science, Technology and Communication (FSTC) > Life Science Research Unit >]
Schmitz, Martine mailto [University of Luxembourg > Faculty of Science, Technology and Communication (FSTC) > Life Science Research Unit >]
Ginolhac, Aurélien mailto [University of Luxembourg > Faculty of Science, Technology and Communication (FSTC) > Life Science Research Unit >]
Rodriguez, Fabien mailto [University of Luxembourg > Faculty of Science, Technology and Communication (FSTC) > Life Science Research Unit >]
Ullmann, Pit mailto [University of Luxembourg > Faculty of Science, Technology and Communication (FSTC) > Life Science Research Unit >]
Qureshi-Baig, Komal mailto []
Frasquilho, Sonia mailto [Integrated Biobank of Luxembourg]
Antunes, Laurent mailto [Integrated Biobank of Luxembourg]
Haan, Serge mailto [University of Luxembourg > Faculty of Science, Technology and Communication (FSTC) > Life Science Research Unit >]
21-Nov-2017
British Journal of Cancer
Nature Publishing Group
117
11
1689-1701
Yes
International
0007-0920
1532-1827
London
United Kingdom
[en] MYO5B, colorectal cancer ; biomarker ; prognostic value
[en] Background: Selecting the most beneficial treatment regimens for colorectal cancer (CRC) patients remains challenging due to a lack of prognostic markers. Members of the Myosin family, proteins recognized to play a major role in trafficking and polarization of cells, have recently been reported to be closely associated with several types of cancer and might thus serve as potential prognostic markers in the context of CRC.
Methods: We used a previously established meta-analysis of publicly available gene expression data to analyse the expression of different members of the Myosin V family, namely MYO5A, 5B, and 5C, in CRC. Using laser-microdissected material as well as tissue microarrays from paired human CRC samples, we validated both RNA and protein expression of MYO5B and its known adapter proteins (RAB8A and RAB25) in an independent patient cohort. Finally, we assessed the prognostic value of both MYO5B and its adapter-coupled combinatorial gene expression signatures.
Results: The meta-analysis as well as an independent patient cohort study revealed a methylation-independent loss of MYO5B expression in CRC that matched disease progression. Although MYO5B mutations were identified in a small number of patients, these cannot be solely responsible for the common down-regulation observed in CRC patients. Significantly, CRC patients with low MYO5B expression displayed shorter overall, disease- and metastasis-free survival, a trend that was further reinforced when RAB8A expression was also taken into account.
Conclusions: Our data identifies MYO5B as a powerful prognostic biomarker in CRC, especially in early stages (stages I and II), which might help stratifying patients with stage II for adjuvant chemotherapy.
University of Luxembourg ; University of Luxembourg: High Performance Computing - ULHPC
Fonds National de la Recherche - FnRF, Fondation Cancer
Identification of new biomarkers for colorectal cancer
Researchers ; Professionals ; Students ; General public
http://hdl.handle.net/10993/34024
10.1038/bjc.2017.352

File(s) associated to this reference

Fulltext file(s):

FileCommentaryVersionSizeAccess
Open access
Loss of Myosin Vb in colorectal cancer is a strong prognostic factor for disease recurrence.pdfPublisher postprint155.99 kBView/Open

Bookmark and Share SFX Query

All documents in ORBilu are protected by a user license.